UBE2V1 antibody (C-Term)

Catalog No. ABIN388931

Product Details anti-UBE2V1 Antibody

Target: UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1 (UBE2V1))

Binding Specificity: AA 113-145, C-Term

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This UBE2V1 antibody is un-conjugated

Application: Western Blotting (WB)

Predicted Reactivity: B, C, Zf, Rat, X

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This UBE2V1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 113-145 amino acids from the C-terminal region of human UBE2V1.

Clone: RB4387

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

Target Details for UBE2V1

Target: UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1 (UBE2V1))

Alternative Name: UBE2V1 (UBE2V1 Products)

Background: The CROC1 isoforms, also known as UBE2V1, show sequence similarity to ubiquitin-conjugating enzymes (UBCs, or E2s) but lack the conserved cysteine residue critical to catalytic activity of E2s.1 Northern blot analysis detected approximately 2.1- and 2.5-kb CROC1 transcripts in all human tissues examined, with the highest levels in brain, skeletal muscle, and kidney. Partial human intestinal epithelial cell cDNAs have been isolated containing the 3-primecoding sequence and 3-prime untranslated region of UBE2V1, also called UEV1.2 UEV1 does not have ubiquitin-conjugating activity in vitro. UEV1 transcripts are downregulated upon differentiation of a colon carcinoma cell line.1 Constitutive expression of exogenous UEV1 protein in these colon carcinoma cells inhibits their capacity to differentiate upon confluence and induces changes in cell cycle behavior associated with inhibition of CDK1. A heterodimeric protein complex has been identified that links TRAF6 to IKK activation.3 Peptide mass fingerprinting analysis revealed that this complex is composed of the ubiquitin conjugating enzyme UBC13 and the UBC-like protein UBE2V1, also called UEV1A. TRAF6, a RING domain protein, functions together with UBC13/UEV1A to catalyze the synthesis of unique polyubiquitin chains linked through lysine-63 (K63) of ubiquitin. Blockade of this polyubiquitin chain synthesis, but not inhibition of the proteasome, prevents the activation of IKK by TRAF6. These results unveil a new regulatory function for ubiquitin, in which IKK is activated through the assembly of K63-linked polyubiquitin chains.

Molecular Weight: 16495

Gene ID: 387522

NCBI Accession: NP_001027459, NP_001244322, NP_001244323, NP_001244325, NP_068823, NP_071887, NP_954595, NP_954673

UniProt: Q13404

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Toll-Like Receptors Cascades